CSIMarket
 
Tenaya Therapeutics Inc   (NASDAQ: TNYA)
Other Ticker:  
 
 
Price: $0.9645 $-0.04 -3.550%
Day's High: $1.07 Week Perf: -8.14 %
Day's Low: $ 0.95 30 Day Perf: -35.27 %
Volume (M): 2,195 52 Wk High: $ 7.01
Volume (M$): $ 2,117 52 Wk Avg: $3.19
Open: $1.01 52 Wk Low: $0.95



 Market Capitalization (Millions $) 83
 Shares Outstanding (Millions) 86
 Employees 55
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -117
 Cash Flow (TTM) (Millions $) -74
 Capital Exp. (TTM) (Millions $) 1

Tenaya Therapeutics Inc
Tenaya Therapeutics Inc is a biotechnology company focused on developing novel treatments for cardiovascular diseases. The company aims to leverage advancements in regenerative medicine and gene therapy to address unmet medical needs in the field. Tenaya Therapeutics is working on various innovative approaches, including reprogramming the body's own cells to regenerate damaged heart tissue and developing gene therapies that can reverse or prevent cardiovascular diseases. The company's ultimate goal is to improve outcomes and quality of life for patients suffering from heart conditions.


   Company Address: 171 Oyster Point Boulevard South San Francisco 94080 CA
   Company Phone Number: 825-6990   Stock Exchange / Ticker: NASDAQ TNYA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADAP        5.44% 
ATRA        18.08% 
BLUE   -10.53%    
IMCR   -3.59%    
IOVA        0.89% 
MGTX        11.09% 
• View Complete Report
   



Clinical Study

Tenaya Therapeutics to Reveal Phase 1b/2 Trial Data for TN-201 Gene Therapy on December 17, 2024,

Published Mon, Dec 16 2024 9:30 PM UTC

Tenaya Therapeutics, a clinical-stage biotechnology company, is poised to make a significant announcement regarding its ongoing efforts to address hypertrophic cardiomyopathy (HCM) a genetic heart condition that leads to thickening of the heart muscle and can result in serious complications. On December 17, 2024, the company will share initial data from its MyPEAK-1 Phase ...

Clinical Study

Tenaya Therapeutics Initiates RIDGE-1 Phase 1b Clinical Trial for TN-401 in Treating PKP2-Associated Arrhythmogenic R...

Published Mon, Nov 25 2024 1:30 PM UTC

Tenaya Therapeutics (NASDAQ: TNYA), a pioneering biotechnology company focusing on gene therapy and heart-related conditions, has announced the commencement of the RIDGE-1 Phase 1b clinical trial with the dosing of the first patient. This trial evaluates TN-401, an innovative AAV9-based gene therapy aimed at addressing Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) a...

Shares

Tenaya Therapeutics Boosts Investor Confidence with Inducement Grants and Strategic Leadership Revamp,

Published Tue, Nov 19 2024 1:01 PM UTC

Tenaya Therapeutics Announces Inducement Grants Amidst Strategic Reorganization to Drive Future GrowthIn a bid to solidify its position as a leader in developing innovative therapies for heart disease, Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company, recently reported the issuance of inducement grants under NASDAQ Listing Rule 5635(c)(4). The ...

Management Changes

Tenaya Therapeutics Revamps Research Leadership to Overcome Financial Challenges and Accelerate Innovative Therapies

Published Thu, Jun 27 2024 9:00 PM UTC

Tenaya Therapeutics Announces Research Leadership Updates
Tenaya Therapeutics, a leading biotechnology company focused on developing treatments for heart diseases, recently made significant changes to its research leadership team. In a press release, the company announced the promotion of Kathy Ivey, Ph.D., to Senior Vice President of Research, while Timothy Hoey, Ph.D.,...

Product Service News

Revamping Cardiac Care: Tenaya Therapeutics' Quest for Precision Heart Medicines

Published Thu, May 2 2024 9:00 PM UTC

Engineering the Future of Precision Heart Medicines: Tenaya Therapeutics Continued Innovation in Capsid Engineering, Gene Editing, and ManufacturingIn the pursuit of developing innovative medicines, scientific advancements in gene and cell therapies have played a pivotal role. Tenaya Therapeutics, a leading biotechnology company, has been at the forefront of this field, sho...






  Tenaya Therapeutics Inc Outlook

On March 18 2024 the Tenaya Therapeutics Inc provided following guidance

Tenaya Therapeutics Inc. has released its financial results for the fourth quarter and full year of 2023, along with a business update. The company is currently conducting the MyPeak-1 Phase 1b clinical trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM), with initial data expected to be available in the second half of 2024.

The company's financial results for 2023 show promising progress in its efforts to develop innovative therapies for cardiovascular diseases. Tenaya Therapeutics remains focused on advancing its pipeline of novel drug candidates, including TN-201, which has the potential to address the unmet medical needs of patients with HCM.

With the upcoming data from ...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com